Keep Contraceptive Arm Long Acting-iMplant (CALM) and Carry On (CALM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
There is very limited information regarding number of bleeding days after replacement of the contraceptive implants (Nexplanon). More detailed information on this topic will help clinicians counsel patients and help women decide if they would like to pursue contraceptive implant replacement.
The investigators will conduct a prospective cohort study of (N=114) among women replacing their contraceptive implant. The primary outcome of the study is the difference in number of bleeding days between the 4-week periods before and after implant replacement. Secondary outcomes include satisfaction with bleeding. Additionally, a secondary outcome will be the number of bleeding days in month 2 and month 3 after replacement of the contraceptive implant. The outcomes will be measured in bleeding diaries and satisfaction surveys.
Through a text messaging application, the investigators will send the participants hyperlinks to the diaries/surveys at the stated time points. Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart (Higham). Participants will complete weekly surveys regarding their satisfaction with their bleeding utilizing a Likert scale. The investigators will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Marisa Hildebrand, MPH
- Phone Number: (858) 329-4464
- Email: mchildeb@health.ucsd.edu
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Reproductive aged women 18-50 years old
- With a contraceptive implant (for patient participants)
- Able to consent in English
- Palpable contraceptive implant
Exclusion Criteria:
- Non-palpable contraceptive implant
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Implant Group
Adults who are choosing to get a replacement Nexplanon and agree to track and report their bleeding patterns for one month before replacement and 3 months after.
|
Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart.
Participants will also complete weekly surveys regarding their satisfaction with their bleeding.
We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of bleeding days during 4 weeks before replacement
Time Frame: 4 weeks (28 days) before day of implant replacement.
|
Number of days participants experienced bleeding during the 4 weeks before implant replacement.
|
4 weeks (28 days) before day of implant replacement.
|
|
Number of bleeding days 4 weeks after replacement
Time Frame: 4 weeks (28 days) after day of implant replacement
|
Number of days participants experienced bleeding during the 4 weeks after implant replacement.
|
4 weeks (28 days) after day of implant replacement
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Satisfaction with bleeding before replacement
Time Frame: 4 weeks (28 days) before day of implant replacement
|
Using a 1-5 Likert scale with 1=Not Satisfied and 5=Very Satisfied, participants will report satisfaction with their bleeding before implant replacement.
|
4 weeks (28 days) before day of implant replacement
|
|
Satisfaction with bleeding after replacement
Time Frame: 4 weeks (28 days) after day of implant replacement
|
Using a 1-5 Likert scale with 1=Not Satisfied and 5=Very Satisfied, participants will report satisfaction with their bleeding after replacement
|
4 weeks (28 days) after day of implant replacement
|
|
Number of bleeding days during the second month after implant replacement
Time Frame: Second month (defined as 29-56 days) after implant replacement
|
Number of days participants experienced bleeding during the second month after implant replacement
|
Second month (defined as 29-56 days) after implant replacement
|
|
Number of bleeding days during the third month post replacement
Time Frame: Third month (defined as 57-84 days) after implant replacement
|
Number of days participants experienced bleeding during the third month after implant replacement
|
Third month (defined as 57-84 days) after implant replacement
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sheila Mody, MD, MPH, University of California, San Diego
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 201908
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
NCT03165838CompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
NCT00258076CompletedFemale Contraception | Contraception
-
NCT00258063Completed
-
NCT02213874CompletedContraception | Contraception Behavior
-
NCT01178125CompletedFemale Contraception | Contraception
-
NCT00254865Completed
-
NCT00236795CompletedFemale Contraception | Contraception
-
NCT00236769CompletedFemale Contraception | Contraception
-
NCT00261482Completed
-
NCT02866279CompletedContraception | Breastfeeding | Postpartum Contraception
Clinical Trials on Track bleeding patterns before and after implant
-
NCT07004517RecruitingPeri-Implantitis | Diagnosis
-
NCT04372901Not yet recruiting
-
NCT06838221Not yet recruitingIntellectual Disability | Caregiver Burden
-
NCT04502420CompletedPostoperative Complications | Abdominal Surgery | Lung Function
-
NCT00411827CompletedKeratoconjunctivitis Sicca
-
NCT04605250CompletedPostoperative Pulmonary Complications
-
NCT05631665Active, not recruitingMenopause | Dyspareunia | Sexual Activity | Atrophy Vulva